NICE flip-flops on Esbriet and Revolade
This article was originally published in Scrip
Executive Summary
NICE, the UK's health technology appraisal body, has made a U-turn on previous decisions and is now recommending both Intermune's Esbriet (pirfenidone) and GlaxoSmithKline's Revolade (eltrombopag).